A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems
Status:
Completed
Trial end date:
1990-06-01
Target enrollment:
Participant gender:
Summary
To determine the maximum long-term dosage of ribavirin (RBV) that is safe and free of serious
side effects in patients with AIDS or AIDS related illnesses. Also, to determine what effect
different dosage levels have on biologic markers of efficacy, such as the amount of the AIDS
virus (HIV) or number of T cells in the patient's blood.
RBV is a new drug capable of inhibiting the growth of the AIDS virus in the laboratory with
little effect on normal human cells. In earlier tests of RBV in AIDS patients, the drug was
well tolerated and safe, and this favorable result suggested that RBV should be more
extensively studied in patients with AIDS and advanced AIDS related complex (ARC).
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)